Patient-Oriented Evidence that Matters (POEMs)  Suggest Potential Clinical Topics for the Choosing Wisely  Campaign

Grad, Roland; Pluye, Pierre; Tang, David Li; Shulha, Michael; Slawson, David C.; Shaughnessy, Allen F.

doi:10.3122/jabfm.2015.02.140226

Cited by 13 publications

(13 citation statements)

References 12 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy that a recent campaign aimed to engage physicians and patients in a conversation about diagnostic tests and procedures in US and Canada (i.e., the Choosing Wisely™ campaign) reported that avoidance of unnecessary diagnostic tests or treatments was the most commonly expected type of health benefit [11], thus reinforcing the need to develop and implement reliable approaches for improving the appropriateness of diagnostic testing.…”

Section: Discussionmentioning

confidence: 97%

Effectiveness of a computerized alert system based on re-testing intervals for limiting the inappropriateness of laboratory test requests

Lippi

Brambilla

Bonelli

et al. 2015

Clinical Biochemistry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Effectiveness of a computerized alert system based on re-testing intervals for limiting the inappropriateness of laboratory test requests

Lippi

Brambilla

Bonelli

et al. 2015

Clinical Biochemistry

View full text Add to dashboard Cite

“…This resonates with campaigns such as Choosing Wisely TM and may help inform addition of genomics topics. 28 Lastly, participants indicated that they would use knowledge gained from Gene Messengers for discussion of impact on family members, highly relevant behaviour in the area of genomic medicine.…”

Section: Discussionmentioning

confidence: 99%

The Gene Messenger Impact Project: An Innovative Genetics Continuing Education Strategy for Primary Care Providers

Carroll

Grad

Allanson

et al. 2016

J Contin Educ Health Prof

View full text Add to dashboard Cite

show abstract

“…We have therefore focused on absolute risk which is recognized as a relevant, valid, and clinically useful measure included in the POEMs outcomes (Patient-Oriented Evidence that Matters). 90,91 Especially, the use of the number needed to treat and the number needed to harm (NNH) as POEMs outcomes have been advocated and therefore adopted in our current study.…”

Section: Discussionmentioning

confidence: 99%

Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis

Gill

Pietrosanu

Gniadecki

2019

Preprint

View full text Add to dashboard Cite

Background: Use of interleukin-17 inhibitors (IL-17i) in psoriasis has been associated with an increased risk of inflammatory bowel disease (IBD). However, the clinical significance of this association is not understood. Objectives: To quantify the absolute risk of IBD in patients with psoriasis treated with IL-17i, stratified by known IBD risk factors. Methods: Literature searches were performed to identify known IBD risk factors and the prevalences were quantified by a meta-analysis of proportions. The Bayesian model was used to estimate the probability of a new-onset or a flare of IBD in patients with psoriasis. Results: The prevalence of Crohn disease (CD) or ulcerative colitis (UC) in the general psoriasis population was 0.0010. Use of IL-17i increased the risk of CD to 0.0037 and UC to 0.0028, translating to a number needed to harm (NNH) of 373 for CD and 564 for UC. In patients who had concomitant hidradenitis suppurativa, the use of IL-17i was associated with a decrease in NNH for CD and UC to 18 and 76, respectively, whereas for patients with a family history of IBD, the NNH values were 6 (for CD) and 10 (for UC). Conclusions: In patients with no risk factors, the probability of IBD flare or onset during IL-17i treatment is negligible and additional IBD screening procedures are not indicated. In contrast, the patients with psoriasis who have hidradenitis suppurativa or first-degree family history of IBD as risk factors should be monitored for signs and symptoms of CD and UC during IL-17i therapy.

show abstract

Patient-Oriented Evidence that Matters (POEMs) Suggest Potential Clinical Topics for the Choosing Wisely Campaign

Cited by 13 publications

References 12 publications

Effectiveness of a computerized alert system based on re-testing intervals for limiting the inappropriateness of laboratory test requests

Effectiveness of a computerized alert system based on re-testing intervals for limiting the inappropriateness of laboratory test requests

The Gene Messenger Impact Project: An Innovative Genetics Continuing Education Strategy for Primary Care Providers

Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis

Contact Info

Product

Resources

About